68 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Roche (Switzerland)CH3 papers
- Merck & Co., Inc., Rahway, NJ, USA (United States)US2 papers
- Novartis (Switzerland)CH2 papers
- Pfizer (United States)US2 papers
- AbbVie (Germany)DE1 paper
- Bayer (United States)US1 paper
- Boehringer Ingelheim (Germany)DE1 paper
- GlaxoSmithKline (United States)US1 paper
- Janssen Research & Development (United States)US1 paper
- Novartis FoundationCH1 paper
- Roche (United States)US1 paper
- Takeda (United States)US1 paper
3 papers
Balancing events, not patients, maximizes power of the logrank test: and other insights on unequal randomization in survival trials
Godwin Yung, Kaspar Rufibach, Marcel Wolbers +2
We revisit the question of what randomization ratio (RR) maximizes power of the logrank test in event-driven survival trials under proportional hazards (PH). By comparing three app…
Principal Stratum Strategy: Potential Role in Drug Development
Björn Bornkamp, Kaspar Rufibach, Jianchang Lin +6
A randomized trial allows estimation of the causal effect of an intervention compared to a control in the overall population and in subpopulations defined by baseline characteristi…
Assessing the Impact of COVID-19 on the Objective and Analysis of Oncology Clinical Trials -- Application of the Estimand Framework
Evgeny Degtyarev, Kaspar Rufibach, Yue Shentu +10
COVID-19 outbreak has rapidly evolved into a global pandemic. The impact of COVID-19 on patient journeys in oncology represents a new risk to interpretation of trial results and it…